A Multicenter, Open-Label, Phase II Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients With Recurrent Glioblastoma Progressed on Bevacizumab Including Therapy

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 22 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olinvacimab (Primary)
Indications Glioblastoma; Gliosarcoma
Focus Adverse reactions
Sponsors PharmAbcine

Most Recent Events

15 Aug 2022 Status changed from recruiting to discontinued.
11 May 2022 According to a PharmAbcine media release, this study has enrolled 18 patients out of 36 total as of April 2022.
14 Sep 2021 Planned End Date changed from 30 Dec 2021 to 30 Jun 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight